close
menu
close
menu
close
menu
close
menu
OXFORD, UK – 04/11/2025 – Responding to increasing demand for reliable pathology reporting across the NHS, Diagnexia UK Limited has achieved UKAS accreditation* to ISO 15189:2022 for its Histology laboratory, Oxford, enabling trusts to access a fully accredited end-to-end histopathology service from specimen to digital report.
The achievement directly addresses mounting challenges facing NHS pathology: workforce capacity constraints, locum spending exceeding £50 million annually, and the critical need for outsourcing partners that maintain internal quality standards while delivering predictable turnarounds. For NHS histopathology teams already stretched thin, this means more efficient, expeditious management of backlog and faster diagnostic answers for patients, accelerating treatment decisions when every day matters.
Unlike traditional providers, Diagnexia offers complete operational flexibility: trusts enter the pathway at any stage ( sample, block, or slide) and exit where needed (blocks, slides or reports). Real-time case tracking eliminates the administrative burden of chasing updates, freeing laboratory managers 2-3 hours daily from manual tasks, while transparent pricing removes hidden costs that complicate procurement planning.
The market response validates this approach, 450% growth in demand since launch of digital service, with more than 27 NHS trusts now relying on the service. Diagnexia maintains 99% compliance with contractual turnaround times while delivering an average 1.2-2 days reporting for pre-prepared cases.
"This accreditation validates what our NHS partners already know, that reliability and speed don't have to be mutually exclusive," said Prof. Runjan Chetty, Chief Medical Officer at Diagnexia. "Clinical teams can now access subspecialist expertise within days, not weeks, while maintaining complete confidence in quality standards."
The Oxford facility combines traditional laboratory excellence with AI-enhanced quality controls at every stage, with cases flowing seamlessly to Diagnexia's network of over 200 GMC-registered subspecialist pathologists. Complete compliance coverage includes UKAS ISO 15189:2022 accreditation, Care Quality Commission registration, NEQAS/EQA participation, and full GDPR compliance.
CEO Donal O'Shea said the accreditation eliminates the compromise between speed, quality, and cost control. "Our end-to-end accreditation provides the risk assurance procurement teams require, while our digital infrastructure delivers the rapid turnaround clinical teams need."
With full integration across major platforms including Sectra, Philips, and Leica, plus expanding IHC capabilities and proven scalability, Diagnexia eliminates implementation friction while supporting growing demand. NHS trusts report significant savings compared to locum pathologist costs, while clinical teams gain access to subspecialty expertise that may not be available locally.
Diagnexia is the clinical branch of Deciphex, providing world-class digital pathology diagnostic services to healthcare institutions worldwide. Its platform connects hospitals to an international network of subspecialty pathologists, delivering rapid, high-quality diagnostic reports. With fully CQC-registered facilities in Oxford (HIstology and digital accessioning lab) and Exeter (digital accessioning lab), Diagnexia is transforming the landscape of pathology reporting in the UK. For more information about Diagnexia, please visit www.diagnexia.com.
*https://www.ukas.com/download-schedule/26823/Medical/
Media contact:
Katie Higgins,
Commercial Marketing Director,
Diagnexia UK Limited
Email: info@diagnexia.com
Phone: +447401290944
OXFORD, UK – 04/11/2025 – Responding to increasing demand for reliable pathology reporting across the NHS, Diagnexia UK Limited has achieved UKAS accreditation* to ISO 15189:2022 for its Histology laboratory, Oxford, enabling trusts to access a fully accredited end-to-end histopathology service from specimen to digital report.
The achievement directly addresses mounting challenges facing NHS pathology: workforce capacity constraints, locum spending exceeding £50 million annually, and the critical need for outsourcing partners that maintain internal quality standards while delivering predictable turnarounds. For NHS histopathology teams already stretched thin, this means more efficient, expeditious management of backlog and faster diagnostic answers for patients, accelerating treatment decisions when every day matters.
Unlike traditional providers, Diagnexia offers complete operational flexibility: trusts enter the pathway at any stage ( sample, block, or slide) and exit where needed (blocks, slides or reports). Real-time case tracking eliminates the administrative burden of chasing updates, freeing laboratory managers 2-3 hours daily from manual tasks, while transparent pricing removes hidden costs that complicate procurement planning.
The market response validates this approach, 450% growth in demand since launch of digital service, with more than 27 NHS trusts now relying on the service. Diagnexia maintains 99% compliance with contractual turnaround times while delivering an average 1.2-2 days reporting for pre-prepared cases.
"This accreditation validates what our NHS partners already know, that reliability and speed don't have to be mutually exclusive," said Prof. Runjan Chetty, Chief Medical Officer at Diagnexia. "Clinical teams can now access subspecialist expertise within days, not weeks, while maintaining complete confidence in quality standards."
The Oxford facility combines traditional laboratory excellence with AI-enhanced quality controls at every stage, with cases flowing seamlessly to Diagnexia's network of over 200 GMC-registered subspecialist pathologists. Complete compliance coverage includes UKAS ISO 15189:2022 accreditation, Care Quality Commission registration, NEQAS/EQA participation, and full GDPR compliance.
CEO Donal O'Shea said the accreditation eliminates the compromise between speed, quality, and cost control. "Our end-to-end accreditation provides the risk assurance procurement teams require, while our digital infrastructure delivers the rapid turnaround clinical teams need."
With full integration across major platforms including Sectra, Philips, and Leica, plus expanding IHC capabilities and proven scalability, Diagnexia eliminates implementation friction while supporting growing demand. NHS trusts report significant savings compared to locum pathologist costs, while clinical teams gain access to subspecialty expertise that may not be available locally.
Diagnexia is the clinical branch of Deciphex, providing world-class digital pathology diagnostic services to healthcare institutions worldwide. Its platform connects hospitals to an international network of subspecialty pathologists, delivering rapid, high-quality diagnostic reports. With fully CQC-registered facilities in Oxford (HIstology and digital accessioning lab) and Exeter (digital accessioning lab), Diagnexia is transforming the landscape of pathology reporting in the UK. For more information about Diagnexia, please visit www.diagnexia.com.
*https://www.ukas.com/download-schedule/26823/Medical/
Media contact:
Katie Higgins,
Commercial Marketing Director,
Diagnexia UK Limited
Email: info@diagnexia.com
Phone: +447401290944
